pI: 9.9055 |
Length (AA): 189 |
MW (Da): 23124 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
16 | 188 | 2p4f (A) | 97 | 296 | 19.00 | 0 | 1 | 1.22574 | -1.11 |
31 | 77 | 1y13 (A) | 56 | 113 | 45.00 | 0.21 | 0.26 | 0.336477 | 1.5 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
NA% percentile | Ring. | Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | intra-erythrocytic - 24 hs, intra-erythrocytic - 32 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, early trophozoite, late trophozoite. | Otto TD PlasmoDB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | gametocyte, early schizont. | PlasmoDB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 16 hs, merozoite, Male Gametocyte. | Otto TD PlasmoDB Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | intra-erythrocytic - 8 hs, Female Gametocyte. | Otto TD Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | Oocyst, Sporozoite. | Zanghi G |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Ortholog group members (OG5_128892)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G34050 | ATP11 molecular chaperone domain-containing protein |
Babesia bovis | BBOV_I000640 | conserved hypothetical protein |
Candida albicans | CaO19_6916 | hypothetical protein |
Candida albicans | CaO19.6916 | assembly of F1-ATPase |
Dictyostelium discoideum | DDB_G0280243 | hypothetical protein |
Drosophila melanogaster | Dmel_CG10340 | CG10340 gene product from transcript CG10340-RA |
Leishmania braziliensis | LbrM.34.1860 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_351940.1 | ATP11 protein, putative |
Leishmania infantum | LinJ.35.1940 | hypothetical protein, conserved |
Leishmania major | LmjF.35.1950 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.34.1950 | hypothetical protein, conserved |
Mus musculus | ENSMUSG00000028710 | ATP synthase mitochondrial F1 complex assembly factor 1 |
Neospora caninum | NCLIV_013200 | hypothetical protein |
Oryza sativa | 4329133 | Os02g0312700 |
Plasmodium berghei | PBANKA_0608200 | ATP synthase mitochondrial F1 complex assembly factor 1, putative |
Plasmodium falciparum | PF3D7_1209800 | ATP synthase mitochondrial F1 complex assembly factor 1, putative |
Plasmodium knowlesi | PKNH_1309700 | ATP synthase mitochondrial F1 complex assembly factor 1, putative |
Plasmodium yoelii | PY01827 | hypothetical protein |
Saccharomyces cerevisiae | YNL315C | Atp11p |
Trypanosoma brucei gambiense | Tbg972.9.9430 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.9.15240 | ATP11 protein, putative |
Trypanosoma congolense | TcIL3000_9_6390 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.509671.40 | ATP11 protein, putative |
Trypanosoma cruzi | TcCLB.510767.50 | ATP11 protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.244.2700 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.244.2700 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.244.2700 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb09.244.2700 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.